EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting APC/C Ubiquitin E3-Ligase Activation with Pyrimidinethylcarbamate Apcin Analogues for the Treatment of Breast Cancer

Maria Kapanidou, Natalie L Curtis, Sandra S Diaz-Minguez, Sandra Agudo-Alvarez, Alfredo Rus Sanchez, Ammar Mayah, Rosette Agena, Paul Brennan, Paula Morales iD, Raul Benito-Arenas iD, Agatha Bastida iD, Victor M Bolanos-Garcia iD

Biomolecules · 2024

DOI: 10.3390/biom14111439 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2024. Verfasst von Maria Kapanidou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological and Medical Sciences, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford OX3 0BP, UK. Hauptthemen laut MEDLINE: Breast Neoplasms, Molecular Docking Simulation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK Oxford Centre., Ministerio de Ciencia, Innovación y Universidades, Spain, Spanish Ministry of Science and Innovation, I-LINK programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Activation of the ubiquitin ligase APC/C by the protein Cdc20 is an essential requirement for proper cell division in higher organisms, including humans. APC/C is the ultimate effector of the Spindle Assembly Checkpoint (SAC), the signalling system that monitors the proper attachment of chromosomes to microtubules during cell division. Defects in this process result in genome instability and cancer. Interfering with APC/C substrate ubiquitylation in cancer cells delays mitotic exit, which induces cell death. Therefore, impairing APC/C function represents an opportunity for the treatment of cancer and malignancies associated with SAC dysregulation. In this study, we report a new class of pyrimidinethylcarbamate apcin analogues that interfere with APC/C activity in 2D and 3D breast cancer cells. The new pyrimidinethylcarbamate apcin analogues exhibited higher cytotoxicity than apcin in all breast cancer cell subtypes investigated, with much lower cytotoxicity observed in fibroblasts and RPE-1 cells. Further molecular rationalisation of apcin and its derivatives was conducted using molecular docking studies. These structural modifications selected from the in silico studies provide a rational basis for the development of more potent chemotypes to treat highly aggressive breast cancer and possibly other aggressive tumour types of diverse tissue origins.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsMolecular Docking SimulationHumansFemaleCell Line, TumorAntineoplastic AgentsCarbamatesCdc20 ProteinsAnaphase-Promoting Complex-CyclosomePyrimidinesDiamines

Stichwörter der Autor:innen

APC/C (Anaphase Promoting Complex/Cyclosome)apcin analoguesbreast cancercell cycle regulationgenome instabilityspindle assembly checkpoint (SAC)

Substanzen

apcinAntineoplastic AgentsCarbamatesCdc20 ProteinsAnaphase-Promoting Complex-CyclosomePyrimidinesDiamines

Autor:innen und Institutionen

  • Department of Biological and Medical Sciences, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford OX3 0BP, UK.
  • Instituto de Química Orgánica, Consejo Superior de Investigaciones Científicas (CSIC), Juan de la Cierva 3, 28006 Madrid, Spain.
  • Department of Bioingeniería, Escuela Nacional de Ciencias Biológicas (ENCB), Instituto Politécnico Nacional, Mexico City 07738, Mexico.
  • Nuffield Department of Medicine (NDM), Old Road Campus, University of Oxford, Oxford OX3 7BN, UK.
  • Instituto de Química Médica, Consejo Superior de Investigaciones Científicas (IQM-CSIC), Juan de la Cierva 3, 28006 Madrid, Spain.

ORCID-Profile: Paula Morales, Raul Benito-Arenas, Agatha Bastida, Victor M Bolanos-Garcia

Förderung

  • Cancer Research UK Oxford Centre.
  • Ministerio de Ciencia, Innovación y Universidades, Spain
  • Spanish Ministry of Science and Innovation, I-LINK programme
  • Nigel Groome PhD Studentship, Oxford Brookes University
  • Oxford Brookes University
  • Cancer Research UK (CRUK)
  • Ministerio de Ciencia, Innovación y Universidades
  • Escuela Nacional de Ciencias Biológicas (ENCB), Instituto Politécnico Nacional

Zitieren

APA

Kapanidou, M., Curtis, N. L., Diaz-Minguez, S. S., Agudo-Alvarez, S., Rus Sanchez, A., Mayah, A., Agena, R., Brennan, P., Morales, P., Benito-Arenas, R., Bastida, A., & Bolanos-Garcia, V. M. (2024). Targeting APC/C Ubiquitin E3-Ligase Activation with Pyrimidinethylcarbamate Apcin Analogues for the Treatment of Breast Cancer. Biomolecules. https://doi.org/10.3390/biom14111439

Vancouver

Kapanidou M, Curtis NL, Diaz-Minguez SS, Agudo-Alvarez S, Rus Sanchez A, Mayah A, et al. Targeting APC/C Ubiquitin E3-Ligase Activation with Pyrimidinethylcarbamate Apcin Analogues for the Treatment of Breast Cancer. Biomolecules. 2024. doi:10.3390/biom14111439

BibTeX
@article{Kapanidou2024,
  author = {Kapanidou, Maria and Curtis, Natalie L and Diaz-Minguez, Sandra S and Agudo-Alvarez, Sandra and Rus Sanchez, Alfredo and Mayah, Ammar and Agena, Rosette and Brennan, Paul and Morales, Paula and Benito-Arenas, Raul and Bastida, Agatha and Bolanos-Garcia, Victor M},
  title = {Targeting APC/C Ubiquitin E3-Ligase Activation with Pyrimidinethylcarbamate Apcin Analogues for the Treatment of Breast Cancer},
  journal = {Biomolecules},
  year = {2024},
  doi = {10.3390/biom14111439}
}
Kostenlos starten →